You are here: Industry Insights > CAR-T

News List

Portonbio Enter CAR-T Partnership with KAEDI contractpharma
June 08, 2021
Porton Biologics has entered a CAR-T partnership with Nanjing KAEDI Biotech. Portonbio will offer CMC services for KAEDI's CAR-T cell therapies with its end-to-end CDMO platform for gene and cell therapies to help accelerate their development process.
Portonbio announced strategic cooperation with KAEDI to accelerate the R&D and production of CAR-T drugs prnasia
June 03, 2021
On May 31, 2021, Porton Biologics Ltd. announced a strategic cooperation with Nanjing KAEDI Biotech, Inc. (hereinafter referred to as KAEDI). Portonbio will offer CMC services for KAEDI's CAR-T cell therapies with its end-to-end CDMO platform for ...
Pregene and Dr. Reddy's Announce License Agreement for Anti-BCMA CAR-T PRG1801 in India prnasia
May 13, 2021
Dr. Reddy's Laboratories Ltd. and Shenzhen Pregene Biopharma Co., Ltd. today announced an agreement whereby Dr Reddy's will acquire an exclusive license in the Republic of India for PRG1801, Pregene's single domain antibody-based anti-BCMA chimeric ...
Cellares Raises $82M To Solve The Biggest Hurdles In Cell Therapy Manufacturing prnasia
May 08, 2021
Cellares Corporation, a life sciences technology company that automates cell therapy manufacturing, announced it has secured $82 million in a Series B round, bringing total funding to date to $100 million.
Janssen seeks EU approval for first CAR-T therapy cilta-cel pharmatimes
May 07, 2021
Johnson & Johnson’s (J&J) pharma division Janssen has filed its first CAR-T cell therapy ciltacabtagene autoleucel (cilta-cel) with the European Medicines Agency (EMA), seeking approval for the treatment of patients with relapsed/refractory multiple ...
Cell therapy for solid tumors may get approval by 2022: GlobalData expresspharma
May 06, 2021
A total of 298 industry-sponsored trials are currently ongoing investigating cell therapies in non-haematological cancers, says GlobalData.
Gracell Biotechnologies Signs Agreement with Lonza to Manufacture Gracell's FasTCAR Product Candidates in the U.S. prnasia
April 01, 2021
Gracell Biotechnologies Inc. announced that the company has entered into a Manufacturing Service Agreement (MSA) with Lonza for clinical manufacturing of Gracell's FasTCAR-enabled CAR-T cell product candidates in the U.S.
Actinium Initiates Patient Enrollment in Iomab-ACT Trial americanpharmaceuticalreview
April 01, 2021
Actinium Pharmaceuticals announced its collaborator, Memorial Sloan Kettering Cancer Center (MSK), has commenced patient enrollment in the Phase 1 study evaluating Iomab-ACT for targeted conditioning prior to treatment with MSK's CD19 targeted ...
Anixa Biosciences, Moffitt Cancer Center File IND Application for Ovarian Cancer CAR-T Therapy americanpharmaceuticalreview
March 25, 2021
Anixa Biosciences announced an IND (Investigational New Drug) application for its ovarian cancer CAR-T (Chimeric Antigen Receptor T-cell) therapy has been filed with the U.S. Food and Drug Administration (FDA).
Novartis receives approval for Kymriah (tisagenlecleucel) by Health Sciences Authority as Singapore's first commercially approved CAR-T therapy prnasia
March 11, 2021
Novartis announced that the Health Sciences Authority (HSA) has approved Kymriah (tisagenlecleucel) as the first commercial chimeric antigen receptor T-cell (CAR-T) therapy in Singapore under the new cell, tissue and gene therapy products (CTGTP) ...

Previous page 1 2 3 4 5 6 7 8 9 10 ... 13 14 Next page